Home

Edward M. MD Kaye

CIK 1522780 · CEO · last filed 2026-08-18

Edward M. MD Kaye is a CEO who has filed 131 SEC Form 4 insider transactions across 6 companies since 2011. The most recent filing, for STOK, was dated Aug 18, 2026. Across all open-market trades the lifetime net is −$18.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.18M

Companies

6

Total Filings

131

Lifetime Open-Market Net

-$18.72M

Filer Profile

Reported Address
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
BEDFORD, MA 01730
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
STOK Director 124,557 $24.98 $3.11M -$8.45M 37 2026-08-18
CYTK Director 10,434 $64.76 $675.7K -$5.51M 51 2026-07-16
Avidity Biosciences, Inc. (RNAM) Delisted Director 0 — — $0 1 2026-02-27
RNA Director 6,692 $8.30 $55.5K $0 5 2025-06-12
SRPT President & CEO 71,229 $18.75 $1.34M -$4.77M 22 2017-08-07
Sarepta Therapeutics, Inc. (AVII) Delisted SVP & Chief Medical Officer — — — $0 2 2012-04-25

Recent Filings

131 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-18 STOK Mixed +13,683 -$402.5K EDGAR
2026-07-16 CYTK Grant (A) +151 $12.5K EDGAR
2026-06-05 STOK Grant (A) — $0 EDGAR
2026-06-01 CYTK Notice (144) −2,933 -$225.1K EDGAR
2026-06-01 CYTK Sell (S) −2,933 -$223.2K EDGAR
2026-05-27 CYTK Grant (A) +2,851 $0 EDGAR
2026-04-15 CYTK Grant (A) +191 $12.5K EDGAR
2026-03-17 STOK Exer (M) +61,750 $0 EDGAR
2026-02-27 Avidity Biosciences, Inc. (RNAM) Delisted Disp (D) −6,692 $0 EDGAR
2026-01-16 CYTK Grant (A) +197 $12.5K EDGAR
Showing 1–10 of 131
Page 1 of 14
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.